Over the past decade, large-scale genetic studies have successfully identified hundreds of genetic variants robustly associated with risk for psychiatric disorders. However, mechanistic insight -- and clinical translation -- continues to lag the pace of risk variant identification, hindered by the sheer number of targets, their predominant non-coding localization, as well as pervasive pleiotropy and incomplete penetrance. Successful next steps require identification of ‘causal’ genetic variants and their proximal biological consequences; placing variants within biologically-defined functional contexts, reflecting specific molecular pathways, cell-types, circuits, and developmental windows; and characterizing the downstream, convergent neurobiological impact of polygenicity within an individual. Here, we discuss opportunities and challenges of high-throughput transcriptomic profiling in human brain, and how transcriptomics can help pinpoint mechanisms underlying genetic risk for psychiatric disorders at a scale necessary to tackle daunting levels of polygenicity. These include transcriptome-wide association studies (TWAS) and related approaches for candidate risk gene prioritization through integration of GWAS with expression quantitative trait loci (eQTL). We outline transcriptomic results informing our understanding of the brain-level molecular pathology of psychiatric disorders, including autism (ASD), bipolar disorder (BD), major depression (MDD), and schizophrenia (SCZ). Finally, we discuss systems-level approaches for integration of distinct genetic, genomic and phenotypic levels, including combining spatially-resolved gene expression and human neuroimaging maps. Results highlight the importance of understanding gene expression (dys)regulation across human brain development as a major contributor to psychiatric disease pathogenesis, from common variants acting as expression quantitative trait loci (eQTL) to rare variants enriched for gene expression regulatory pathways.
Visuospatial working memory (vsWM) requires information transfer among multiple cortical regions, from primary visual (V1) to prefrontal (PFC) cortices. This information is conveyed via layer 3 glutamatergic neurons whose activity is regulated by gamma-aminobutyric acid (GABA)ergic interneurons. In layer 3 of adult human neocortex, molecular markers of glutamate neurotransmission were lowest in V1 and highest in PFC, whereas GABA markers had the reverse pattern. Here, we asked if these opposite V1–visual association cortex (V2)–posterior parietal cortex (PPC)–PFC gradients across the vsWM network are present in layer 3 of monkey neocortex, when they are established during postnatal development, and if they are specific to this layer. We quantified transcript levels of glutamate and GABA markers in layers 3 and 6 of four vsWM cortical regions in a postnatal developmental series of 30 macaque monkeys. In adult monkeys, glutamate transcript levels in layer 3 increased across V1–V2–PPC–PFC regions, whereas GABA transcripts showed the opposite V1–V2–PPC–PFC gradient. Glutamate transcripts established adult-like expression patterns earlier during postnatal development than GABA transcripts. These V1–V2–PPC–PFC gradients and developmental patterns were less evident in layer 6. These findings demonstrate that expression of glutamate and GABA transcripts differs across cortical regions and layers during postnatal development, revealing potential molecular substrates for vsWM functional maturation.
21 September 2024 in Journal of Psychiatric Research